[go: up one dir, main page]

FI3592384T3 - Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään - Google Patents

Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään

Info

Publication number
FI3592384T3
FI3592384T3 FIEP18711275.0T FI18711275T FI3592384T3 FI 3592384 T3 FI3592384 T3 FI 3592384T3 FI 18711275 T FI18711275 T FI 18711275T FI 3592384 T3 FI3592384 T3 FI 3592384T3
Authority
FI
Finland
Prior art keywords
disease
antibody
seq
region
antigen
Prior art date
Application number
FIEP18711275.0T
Other languages
English (en)
Inventor
Stephan Fischer
Karsten Beckmann
Original Assignee
Mab Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mab Discovery Gmbh filed Critical Mab Discovery Gmbh
Application granted granted Critical
Publication of FI3592384T3 publication Critical patent/FI3592384T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

Patenttivaatimukset
1. Monoklonaalinen vasta-aine tai sen antigeenia sitova fragmentti, joka kykenee sitoutumaan ihmisen IL-1R7:ään, jossa vasta-aine käsittää a) SEO ID nro: 1189:n VH-alueen ja käsittää SEO ID nro: 309:n CDHR1H-alueen, SEQ ID nro: 457:n CDHR2H-alueen ja SEQ ID nro: 605:n CDR3H-alueen, ja b) SEQ ID nro 1198:n tai 1203:n VL-alueen ja käsittää SEQ ID nro: 753:n CDR1L-alueen, SEO ID nro 901:n CDR2L-alueen, ja SEO ID nro: 1049:n tai 1205:n CDR3L-alueen.
2. Patenttivaatimuksen 1 mukainen vasta-aine tai sen antigeenia sitova fragmentti, jossa vasta-aine on jänis/ihminen-kimeerinen vasta-aine.
3. Minkä tahansa edeltävän patenttivaatimuksen mukainen vasta- aine tai sen antigeeniä sitova fragmentti, joka ilmentää vähentynyttä affiniteettia ihmisen Fcy-reseptoreihin verrattuna villityyppiseen IgG Fcy:hyn.
4. Minkä tahansa edeltävän patenttivaatimuksen mukainen vasta- aine tai sen antigeenia sitova fragmentti, jossa ihmisen Fcy:n välittämä signalointi on vähentynyt verrattuna villityyppiseen IgG Fcy-reseptorin signalointiin.
5. Minkä tahansa edeltävän patenttivaatimuksen mukainen vasta- aine tai sen antigeenia sitova fragmentti käytettäväksi IL-18 välitteisen sairauden hoidossa, joka on immuunisairaus tai autoimmuunisairaus tai tulehdussairaus tai autoinflammatorinen sairaus tai sydän- ja verisuonitauti.
6. Vasta-aine tai sen antigeenia sitova fragmentti käytettäväksi patenttivaatimuksen 5 mukaisesti, jossa sairaus on valittu ryhmästä, joka koostuu 1 tai 2 tyyppisestä diabeteksesta, tulehduksellisesta suolistosai- raudesta, Chronin taudista (CD); haavaisesta koliitista (UC), multippeliskle- roosista, sarkoidoosista, jättisoluisesta niveltulehduksesta (GCA) ikään liittyvästä makuladegeneraatiosta (AMD) kroonisesta obstruktiivisesta keuhkosairaudesta (COPD), aikuisiän Stillin taudista (AOSD), systeemisestä nuoruusiän idiopaattisesta niveltulehduksesta (SJIA) vakavasta astmasta, Uveniitista, Geografisesta atrofiasta, ateroskleroorista ja tuumori-indusoidusta kroonisesta tulehduksesta.
7. Farmaseuttinen koostumus, joka käsittää farmaseuttisesti hyväksyttyä kantajaa ja farmaseuttisesti vaikuttavan määrän minkä tahansa —patenttivaatimuksen 1-4 mukaista vasta-ainetta tai sen antigeenia sitovaa fragmenttia.
FIEP18711275.0T 2017-03-09 2018-03-09 Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään FI3592384T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160191 2017-03-09
PCT/EP2018/055934 WO2018162724A1 (en) 2017-03-09 2018-03-09 Antibodies specifically binding to human il-1r7

Publications (1)

Publication Number Publication Date
FI3592384T3 true FI3592384T3 (fi) 2025-09-29

Family

ID=58265918

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18711275.0T FI3592384T3 (fi) 2017-03-09 2018-03-09 Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään

Country Status (13)

Country Link
US (1) US11352432B2 (fi)
EP (2) EP4623992A2 (fi)
JP (1) JP7046089B2 (fi)
CN (2) CN110382002B (fi)
AU (1) AU2018232883B2 (fi)
CA (1) CA3055256A1 (fi)
DK (1) DK3592384T3 (fi)
ES (1) ES3042097T3 (fi)
FI (1) FI3592384T3 (fi)
LT (1) LT3592384T (fi)
PT (1) PT3592384T (fi)
WO (1) WO2018162724A1 (fi)
ZA (1) ZA201905341B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230050773A1 (en) * 2019-12-04 2023-02-16 Medimmune Limited Antibodies against lif and uses thereof
CN115443150A (zh) * 2019-12-17 2022-12-06 德克萨斯大学系统董事会 新型ddr1抗体和其用途
WO2022026360A2 (en) * 2020-07-28 2022-02-03 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
CN114276450B (zh) * 2020-09-27 2023-08-29 江苏荃信生物医药股份有限公司 抗人il-17a单克隆抗体及其用途
EP4228674A4 (en) * 2020-10-15 2025-01-29 Bioincept LLC SYSTEMS, COMPOSITIONS AND METHODS FOR DETERMINING THE VIABILITY OF EMBRYOS
WO2022256739A2 (en) * 2021-06-04 2022-12-08 Nonagen Therapeutics Corporation Antibody specific for bcl-6 and methods of use
EP4463183A1 (en) * 2022-01-11 2024-11-20 Board of Regents, The University of Texas System Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof
WO2024086852A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
CN115819580B (zh) * 2022-11-23 2023-09-05 武汉爱博泰克生物科技有限公司 针对人il-12的高亲和力兔单克隆抗体及其应用
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法
CN116355094B (zh) * 2023-02-21 2023-10-20 武汉爱博泰克生物科技有限公司 抗小鼠白介素12的单克隆抗体及制备方法
CN119569860B (zh) * 2023-09-07 2025-11-18 菲鹏生物股份有限公司 一种抗p24抗体及其应用
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
CN117603357B (zh) * 2023-11-29 2024-09-03 武汉爱博泰克生物科技有限公司 针对人孕激素受体的兔单克隆抗体及其应用
WO2025147472A1 (en) * 2024-01-02 2025-07-10 Phanes Therapeutics, Inc. Anti-611-ctf p95her2 antibodies and uses thereof
CN118240074A (zh) * 2024-04-30 2024-06-25 杭州旭科生物技术有限公司 抗艾滋病毒p24抗原的单克隆抗体及其应用和产品
CN118465262B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 一种测定细胞制剂中逆转录病毒载体残留的方法
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338515A3 (en) 2000-02-10 2011-11-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
MX2007012197A (es) * 2005-03-31 2007-11-21 Biomedics Inc Anticuerpo monoclonal anti-cd20.
DK2336315T3 (da) * 2005-12-01 2017-11-06 Nuevolution As Fremgangsmåde til enzymatisk kodning ved effektiv syntese af store biblioteker
AU2007217563A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
US7615220B2 (en) * 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
US7914734B2 (en) * 2007-12-19 2011-03-29 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
WO2009155724A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
NZ624935A (en) * 2009-10-19 2016-01-29 Theranos Inc Integrated health data capture and analysis system
BR112013015508B1 (pt) 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP3076980A4 (en) * 2013-12-06 2017-08-16 Fuwan Pty Ltd A method of treating neoplasia
WO2016199964A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
PT3219727T (pt) * 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
TWI838670B (zh) * 2020-12-22 2024-04-11 美商基利科學股份有限公司 經取代之吲哚化合物
WO2022140325A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds

Also Published As

Publication number Publication date
ZA201905341B (en) 2021-10-27
AU2018232883A1 (en) 2019-09-19
JP2020510013A (ja) 2020-04-02
EP4623992A2 (en) 2025-10-01
EP3592384B1 (en) 2025-07-02
EP3592384A1 (en) 2020-01-15
AU2018232883B2 (en) 2024-10-17
CN110382002B (zh) 2025-08-15
ES3042097T3 (en) 2025-11-18
CA3055256A1 (en) 2018-09-13
US11352432B2 (en) 2022-06-07
JP7046089B2 (ja) 2022-04-01
DK3592384T3 (da) 2025-09-15
LT3592384T (lt) 2025-10-10
US20210130478A1 (en) 2021-05-06
PT3592384T (pt) 2025-10-01
NZ756707A (en) 2024-07-05
WO2018162724A1 (en) 2018-09-13
CN120842411A (zh) 2025-10-28
CN110382002A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
FI3592384T3 (fi) Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään
Akamatsu et al. Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
JP2012501669A5 (fi)
JP2012501670A5 (fi)
JP2018121657A5 (fi)
JP2012524071A5 (fi)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
JP2012516158A5 (fi)
JP2017510567A5 (fi)
JP2012525829A5 (fi)
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
HRP20191334T1 (hr) Anti-fcrn antitijela
Camacho-Villegas et al. Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic use
JP2016508984A5 (fi)
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
JP2014518883A5 (fi)
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2009519718A5 (fi)
JP2013545455A5 (fi)
JP2009523154A5 (fi)
HRP20150623T1 (hr) Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen
RU2016136639A (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины